Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
根據最新的財務報表(Form-10K),Bright Horizons Family Solutions Inc 的總資產為 $0,淨isProfitable}為 $0
OMMH 的關鍵財務比率是什麼?
Bright Horizons Family Solutions Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Omnimmune Holdings Inc 的收入按細分市場或地理位置如何劃分?
Bright Horizons Family Solutions Inc 最大收入來源為 Full Service Center-Based Child Care,在最近的收益報告中收入為 2,081,119,000。就地區而言,North America 是 Bright Horizons Family Solutions Inc 的主要市場,收入為 2,090,922,000。
Omnimmune Holdings Inc 是否盈利?
無,根據最新的財務報表,Bright Horizons Family Solutions Inc 的淨損失為 $0